Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma (HG146)
A Phase Il Clinical Study to Evaluate the Efficacy and Safety of HG146 Capsules in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma.
This is a Phase II, open-label, non-randomized, multicenter study to evaluate the clinical efficacy and safety of HG146 in participants with recurrent or metastatic adenoid cystic carcinoma. This study is divided into two stages. 40 participants will be enrolled in the first stage. The efficacy and safty data will apply to make go or no go decision. Then the second stage will continue to enroll 100 Particapants.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Jie Shen
- 電話番号:8211 8268-85197385
- メール:jie.shen@hitgen.com
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国、200000
- 募集
- Shanghai Oriental Hospital
-
コンタクト:
- Ye Guo
- 電話番号:8268-85197385
- メール:pattrickguo@gmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Signed informed consent form (ICF) and able to comply with study.
- Age ≥18 years, gender unlimited.
- Recurrent or metastatic adenoid cystic carcinoma with evidence of disease progression (imaging progression or clinical evidence of progression) within one year of histological or cytological diagnosis.
- Estimated survival >12 weeks, as determined by the investigator.
- The United States Eastern Cancer Consortium (ECOG) physical status score 0-1.
- Has adequate organ function.
- At least 1 measurable tumor lesion according to RECISTv1.1 criteria.
Exclusion Criteria:
- Symptomatic central nervous system (CNS) metastases that have required steroids within 4 weeks prior to first dose of study treatment.
- Received prior therapies targeting HDAC.
- Chemotherapy was received within 21 days before the first administration of the study treatment, and anti-tumor therapy such as radiotherapy, biotherapy, targeted therapy, and immunotherapy was received within 28 days before the first administration of the study treatment [small molecule targeted drugs, Chinese medicines with anti-tumor indications, and local palliative radiotherapy were 14 times before the first administration of the study drug.
- Used strong CYP3A4 inhibitors or inducers within 7 days before the first use of the investigational drug.
- Major surgery or major injury <=28 days before the first dose of study treatment,or anticipated major surgery during the study.
- Prior allogeneic bone marrow transplantation or other solid organ transplantation
- Active infection requiring systemic treatment.
- Current or past presence of other malignancies (other than adequately treated basal cell or squamous cell carcinoma of the skin and carcinoma in situ of the cervix), unless radical treatment has been performed and there is no evidence of recurrence and metastasis in the last 5 years.
- A person is known to be allergic to any active ingredient or excipient of the investigational drug.
- Pregnant or lactating women.
- patients with drug abuse or chronic alcohol abuse that may affect the evaluation of the test results.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Clinical Trial of HG146 Administered to participants with Adenoid cystic carcinoma
Experimental: HG146 Monotherapy Arm Description: Participants will receive HG146 per os at every two days intervals (qod) for 14 consecutive days,7 days off, 21 days/ cycle. |
HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
objective response rate (ORR)
時間枠:From enrollment to the end of treatment at 4 weeks
|
ORR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
6 Months Progression-Free Survival (PFS)
時間枠:From enrollment to treatment at 6 months.
|
PFS will be assessed by the investigators using RECIST v. 1.1 |
From enrollment to treatment at 6 months.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS)
時間枠:From enrollment to treatment at 12 months
|
PFS will be assessed by the investigators using RECIST v1.1 |
From enrollment to treatment at 12 months
|
|
Duration of response (DoR)
時間枠:From enrollment to the end of treatment at 4 weeks
|
DOR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Disease control rate (DCR)
時間枠:From enrollment to the end of treatment at 4 weeks
|
DCR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Overall survival (OS)
時間枠:From enrollment to the end of treatment at 4 weeks
|
OS will be assessed by the investigators |
From enrollment to the end of treatment at 4 weeks
|
|
Time-to-response (TTR)
時間枠:From enrollment to the end of treatment at 4 weeks
|
TTR will be assessed by the investigators using RECIST v1.1 |
From enrollment to the end of treatment at 4 weeks
|
|
Population pharmacokinetics (PopPK)
時間枠:From Cycle1 Day7 to Day13, 21 days per cycle
|
PopPK will be detected to predict exposure level of HG146 in human body. |
From Cycle1 Day7 to Day13, 21 days per cycle
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ye Guo、Shanghai Oriental Hospital
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- HG146CN201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。